Data / Drug companies / Dexlansoprazole
Dexlansoprazole: 12 companies and 23 products in the FDA NDC directory
Dexlansoprazole is listed in the FDA National Drug Code Directory by 12 companies, with 23 products in commercial distribution. 20 of the products (87.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, delayed release; capsule, delayed release pellets, and the newest product started marketing on November 4, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 23
- Generic (ANDA) products
- 20 (87.0%)
- Application numbers
- 5
- Routes
- Oral
- Brand names
- Dexilant
- openFDA record search
- api.fda.gov
Companies that list dexlansoprazole
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 3 | capsule, delayed release | Generic drugs (ANDA) | December 1, 2022 |
| Bryant Ranch Prepack | 3 | capsule, delayed release | Generic drugs (ANDA) | June 10, 2023 |
| Alembic Pharmaceuticals Inc. | 2 | capsule, delayed release | Generic drugs (ANDA) | November 14, 2025 |
| Alembic Pharmaceuticals Limited | 2 | capsule, delayed release | Generic drugs (ANDA) | November 14, 2025 |
| Golden State Medical Supply, Inc. | 2 | capsule, delayed release | Generic drugs (ANDA) | September 16, 2022 |
| Mylan Pharmaceuticals Inc. | 2 | capsule, delayed release pellets | Generic drugs (ANDA) | January 22, 2024 |
| Par Health USA, LLC | 2 | capsule, delayed release | Generic drugs (ANDA) | June 10, 2023 |
| Takeda Pharmaceuticals America, Inc. | 2 | capsule, delayed release | New drug applications (NDA) | April 12, 2010 |
| Upsher-Smith Laboratories, LLC | 2 | capsule, delayed release | Generic drugs (ANDA) | December 1, 2022 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | capsule, delayed release | Generic drugs (ANDA) | September 16, 2022 |
| Bryant Ranch Prepack | 1 | capsule, delayed release | Generic drugs (ANDA) | December 1, 2022 |
| Remedyrepack Inc. | 1 | capsule, delayed release | Generic drugs (ANDA) | November 4, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, delayed release | 21 | 91.3% |
| Capsule, delayed release pellets | 2 | 8.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 20 | 87% |
| New drug applications (NDA) | 2 | 8.7% |
| Authorized generics (NDA) | 1 | 4.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Proton Pump Inhibitor | 23 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.